Implication de la voie alterne du complément dans les ...

More documents

Recommendations

Info

60 M. R. DAHA également une contribution du tissu-même dans l’activation du complément. D’une part, ces événements sont régulés par différents inhibiteurs du complément liés à la membrane et sont de plus contrôlés par les inhibiteurs en phase fl uide. D’autre part, lorsqu’une modulation tissulaire se produit, celle-ci peut être associée à une perte du contrôle du complément et à une amplifi cation de l’infl ammation. À cet égard, la contribution de la properdine devrait être reconnue comme un régulateur positif important de l’atteinte tissulaire. BIBLIOGRAPHIE 1. WALPORT MJ. Complement. First of two parts. N Engl J Med, 2001, 344 : 1058-1066. 2. WALPORT MJ. Complement. Second of two parts. N Engl J Med, 2001, 344 : 1140-114. 3. SELANDER B, MARTENSSON U, WEINTRAUB A. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest, 2006, 116 : 1425-1434. 4. DAHA MR, VAN KOOTEN C, ROOS A. Compliments from complement: a fourth pathway of complement activation? Nephrol Dial Transplant, 2006, 21 : 3374-3376. 5. PETERSEN SV, THIEL S, JENSENIUS JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol, 2001, 38 : 133-149. 6. HOLMSKOV U, THIEL S, JENSENIUS JC. Collectins and fi colins: humoral lectins of the innate immune defense. Annu Rev Immunol, 2003, 21 : 547-578. 7. MATSUSHITA M, ENDO Y, FUJITA T. Complement-activating complex of fi colin and mannose-binding lectin-associated serine protease. J Immunol, 2000, 164 : 2281-2284. 8. MATSUSHITA M, KURAYA M, HAMASAKI N et al. Activation of the lectin complement pathway by H-fi colin (Hakata antigen). J Immunol, 2002, 168 : 3502-3506. 9. FEARON DT, DAHA MR, WEILER JM et al. The natural modulation of the amplifi cation phase of complement activation. Transplant Rev, 1976,32 :12-25. 10. KEMPER C, HOURCADE DE. Properdi. New roles in pattern recognition and target clearance. Mol Immunol, 2008, 45 : 4048-4056. 11. KEMPER C, HOURCADE DE. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci USA, 2008, 105 : 9023-9028. 12. XU W, BERGER SP, TROUW LA et al. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol, 2008, 180 : 7613- 7621. 13. DE VRIES B, MATTHIJSEN RA, WOLFS TG et al. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and infl ammation. Transplantation, 2003, 75 : 375-382. 14. PICKERING MC, BOTTO M, TAYLOR PR et al. Systemic lupus erythematosus, complement defi ciency, and apoptosis. Adv Immunol, 2000, 76 : 227-324. 15. RIEDEMANN NC, WARD PA. Complement in ischemia reperfusion injury. Am J Pathol, 2003, 162 : 363-367. 16. ZHOU W, FARRAR CA, ABE K et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest, 2000, 105 : 1363-1371. 17. BENE MC, FAURE GC. Composition of mesangial deposits in IgA nephropathy: Complement factors. Nephron, 1987, 46 : 219. 18. RAUTERBERG EW, LIEBERKNECHT HM, WINGEN AM et al. Complement membrane attack (MAC) in idiopathic IgA glomerulonephritis. Kidney Int, 1987, 31 : 820-829. 19. HISANO S, MATSUSHITA M, FUJITA T et al. Activation of the lectin complement pathway in Henoch- Schönlein purpura nephritis. Am J Kidney Dis, 2005, 45 : 295-302.
IMPLICATION DE LA VOIE ALTERNE DU COMPLÉMENT DANS LES NÉPHROPATHIES 61 20. ROOS A, RASTALDI MP, CALVARESI N et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol, 2006, 17 : 1724-1734. 21. WATTS RA, LANE SE, SCOTT DG et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis, 2001, 60 : 1156-1157. 22. CHEN M, YU F, ZHANG Y et al. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine, 2008, 87 : 203-209. 23. SHINGU M, NONAKA S, NISHIMUKAI H et al. Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils. Clin Exp Immunol, 1992, 90 : 72-78. 24. VOGT W. Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology, 1996, 195 : 334-346. 25. VENGE P, OLSSON I. Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity. J Immunol, 1975, 115 : 1505-1508. 26. XIAO H, SCHREIBER A, HEERINGA P et al. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol, 2007, 170 : 52-64. 27. SCHREIBER A, XIAO H, JENNETTE JC et al. C5a Receptor Mediates Neutrophil Activation and ANCA- Induced Glomerulonephritis. J Am Soc Nephrol, 2009, 20 : 289-298. 28. XIAO H, HEERINGA P, HU P et al. Antineutrophil cytoplasmic autoantibodies specifi c for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest, 2002, 110 : 955- 963. 29. HUUGEN D, VAN ESCH A, XIAO H et al. Inhibition of complement factor C5 protects against antimyeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int, 2007, 71 : 646- 654. 30. CHEN M, XING GQ, YU F et al. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant, 2009, 24 : 1247- 1252.
Page 1 and 2: IMPLICATION DE LA VOIE ALTERNE DU C
Page 7: IMPLICATION DE LA VOIE ALTERNE DU C

Implication de la voie alterne du complément dans les ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?